JP2024523559A5 - - Google Patents

Info

Publication number
JP2024523559A5
JP2024523559A5 JP2023579554A JP2023579554A JP2024523559A5 JP 2024523559 A5 JP2024523559 A5 JP 2024523559A5 JP 2023579554 A JP2023579554 A JP 2023579554A JP 2023579554 A JP2023579554 A JP 2023579554A JP 2024523559 A5 JP2024523559 A5 JP 2024523559A5
Authority
JP
Japan
Prior art keywords
compound
human
pharmaceutical product
approximately
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073148 external-priority patent/WO2022272300A1/en
Publication of JP2024523559A publication Critical patent/JP2024523559A/ja
Publication of JP2024523559A5 publication Critical patent/JP2024523559A5/ja
Pending legal-status Critical Current

Links

JP2023579554A 2021-06-24 2022-06-24 アルドステロン合成酵素阻害剤を使用する方法 Pending JP2024523559A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163214521P 2021-06-24 2021-06-24
US63/214,521 2021-06-24
US202163290364P 2021-12-16 2021-12-16
US63/290,364 2021-12-16
PCT/US2022/073148 WO2022272300A1 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
JP2024523559A JP2024523559A (ja) 2024-06-28
JP2024523559A5 true JP2024523559A5 (cg-RX-API-DMAC7.html) 2025-06-23

Family

ID=84545863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579554A Pending JP2024523559A (ja) 2021-06-24 2022-06-24 アルドステロン合成酵素阻害剤を使用する方法

Country Status (10)

Country Link
US (1) US20240277698A1 (cg-RX-API-DMAC7.html)
EP (1) EP4358959A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523559A (cg-RX-API-DMAC7.html)
KR (1) KR20240035483A (cg-RX-API-DMAC7.html)
AU (2) AU2022299103B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023027025A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223211A1 (cg-RX-API-DMAC7.html)
IL (1) IL309428A (cg-RX-API-DMAC7.html)
MX (1) MX2023015121A (cg-RX-API-DMAC7.html)
WO (1) WO2022272300A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026521801A (ja) * 2023-06-29 2026-07-01 アストラゼネカ アイルランド リミテッド バクスドロスタットの結晶形、並びにその製造方法及びその使用
CN121712504A (zh) * 2023-07-27 2026-03-20 矿物疗法公司 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法
IL329013A (en) * 2023-12-15 2026-08-01 Astrazeneca Ireland Ltd SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension
WO2026120166A1 (en) 2024-12-06 2026-06-11 AstraZeneca Ireland Limited Tablet formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
AU4866196A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
CA2832996C (en) * 2011-04-26 2019-05-07 Merck Sharp & Dohme Corp. Tricyclic triazole compounds and their use as aldosterone synthase inhibitors
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives

Similar Documents

Publication Publication Date Title
JPH06102622B2 (ja) 肥満の治療
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
JP2022536623A (ja) 肺動脈性肺高血圧症の治療方法
JP3313714B2 (ja) 抗虚血薬剤
JP2022533968A5 (cg-RX-API-DMAC7.html)
KR20010015918A (ko) 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
JP2024539476A5 (cg-RX-API-DMAC7.html)
JP2023531930A5 (cg-RX-API-DMAC7.html)
JP2024525164A5 (cg-RX-API-DMAC7.html)
JP2000513356A (ja) エナラプリルとロサルタンの組成物
JP2008501023A (ja) 小児患者での癌の治療
JP2025511403A5 (cg-RX-API-DMAC7.html)
JP3885135B2 (ja) C型又は非b非c型肝炎ウイルスによる肝機能異常の改善剤
JPH09216831A (ja) 抗ウイルス剤
JP2008535907A5 (cg-RX-API-DMAC7.html)
JP4628622B2 (ja) 冠状動脈移植片血管攣縮の治療または予防方法
SK284581B6 (sk) Použitie levosimendanu alebo jeho farmaceuticky prijateľnej soli na výrobu liečiva na liečenie pľúcnej hypertenzie
JP2024527715A5 (cg-RX-API-DMAC7.html)
JP4965791B2 (ja) 敗血症性ショックの治療方法
CN113616651B (zh) 一种复方降压药物组合物及其应用
Hart et al. ACE inhibition versus calcium antagonism in the treatment of mild to moderate hypertension: a multicentre study. Ireland-Netherlands Lisinopril-Nifedipine Study Group
KR20250155479A (ko) 칸데사르탄, 암로디핀 및 인다파미드를 포함하는 고혈압 예방 또는 치료용 약제학적 복합제제
Man in’t Veld The place of isradipine in the treatment of hypertension
WO2025132532A1 (en) Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension
WO2025221288A1 (en) Treatment of diseases via administration of buntanetap and an antihypertensive agent